Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NBTY president

This article was originally published in The Tan Sheet

Executive Summary

CFO Harvey Kamil adds president's title, supplement firm announces Jan. 8. Former president Scott Rudolph retains position as chairman and CEO. Kamil has been NBTY's chief financial officer since joining the firm in 1982; company currently has no plans to hire someone to assume his CFO duties...

You may also be interested in...



Publisher's Spotlight: Clinical And Research Excellence Honored At The Citeline Awards

Informa Pharma Intelligence congratulates the winners of the fifth annual awards. 

Publisher's Spotlight: Clinical And Research Excellence Honored At The Citeline Awards

Informa Pharma Intelligence congratulates the winners of the fifth annual awards. 

Ultragenyx Enters Duchenne Gene Therapy Space In $295m Deal With Solid Biosciences

Ultragenyx enters a competitive and complicated market, but the combination of its manufacturing platform with Solid’s transgene could provide an advantage. 

Topics

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel